| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Eculizumab |
| Brand | Soliris® |
| Indication | For the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in the Irish healthcare setting. |
| Assessment Process | |
| Rapid review commissioned | 20/01/2010 |
| Rapid review completed | 20/03/2010 |
| Rapid review outcome | Reimbursement not recommended |
| NCPE assessment re-commenced | 15/07/2013 |
| NCPE assessment completed | 14/10/2013 |
| NCPE assessment outcome | Reimbursement not recommended. |
Alexion Pharma UK. Ltd have failed to demonstrate the cost-effectiveness of eculizumab (Soliris®) for the treatment of PNH in the Irish healthcare setting.
Pharmacoeconomic Reassessment
The NCPE do not believe that eculizumab (Soliris®) is value for money for the treatment of patients with PNH in the Irish Healthcare setting
